Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Completed · Phase 1/Phase 2
Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
In brief
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving arsenic trioxide together with etanercept and to see how well it works in treating patients with myelodysplastic syndromes.
Key facts
- Study ID
- NCT00093366
- Run by
- Fred Hutchinson Cancer Center
- People needed
- 32
- Starts
- 2004-06-01
- Expected to finish
- 2006-07-01
- Last updated by the study team
- 2011-11-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.